

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **LIFETECH SCIENTIFIC CORPORATION**

**先健科技公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8122)**

### **PRICE SENSITIVE INFORMATION**

This announcement is made pursuant to Rule 17.10 of the GEM Listing Rule.

The Board wishes to inform the shareholders of the Company and potential investors that it is expected to record a considerable reduction in operating profit margin (before taking into account offering expenses and change in fair value of convertible redeemable preferred shares) for the fourth quarter of the year ended 31 December 2011 (the “Fourth Quarter”) as compared to that for first three quarters (both results were unaudited), and the profit for the period of the Group for the year ended 31 December 2011 is expected to be slightly lower than that was recorded for the three quarters ended 30 September 2011 as announced on 13 November 2011.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

This announcement is made by the board (the “Board”) of directors (the “Directors”) of LifeTech Scientific Corporation (the “Company”) and its subsidiaries (collectively referred to as the “Group”) pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on the Growth Enterprise Market (the “GEM Listing Rules”) of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”).

After preliminary review by the Company's management based on the management accounts of the Company, the Directors of the Company wishes to inform the shareholders of the Company and the potential investors that it is expected to record a considerable reduction in operating profit margin (before taking into account offering expenses and change in fair value of convertible redeemable preferred shares) for the fourth quarter of the year ended 31 December 2011 as compared to that for the first three quarters, primarily due to a combination of the following: (i) the increase in the selling and distribution expenses as a result of additional promotion and marketing efforts and expansion of sales force in the Fourth Quarter, and (ii) the increase in the research and development expenses as a result of the increase of expenses relating to product registration and clinical trials of certain research and development projects that have been ahead of schedule and additional recruitment of staff during the Fourth Quarter.

Despite the unprofitable result of the Fourth Quarter, the Board considers that the Group's overall financial positions are healthy and the Board remains positive on the prospects of the Group. The Board will constantly keep reviewing the Group's operations results and make adjustments to its strategies and operations to improve its business performance and Company's shareholders' return.

The Company is in the process of finalizing the Group's audited final results for the year ending 31 December 2011. The information contained in this announcement is only based on a preliminary assessment made by the Board with reference to the current unaudited consolidated management accounts of the Group, and such information has not been finalized by the Company's independent auditor. Shareholders of the Company and potential investors are advised to refer to the details of the Group's final results for the year ending 31 December 2011 which is expected to be released in the end of March 2012.

**Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.**

By order of the Board  
**LifeTech Scientific Corporation**  
**XIE Yuehui**  
*Chairman and Executive Director*

Hong Kong, 16 March 2012

*As at the date of announcement, the Board comprises Mr. XIE Yuehui and Mr. ZHAO Yiwei Michael being executive directors of the Company; Mr. ZENG Min Frank, Mr. LI Gabriel, Mr. WU Jianhui and Ms. CONG Ning being non-executive directors of the Company; and Mr. LIANG Hsien Tse Joseph, Mr. ZHANG Xingdong, Mr. ZHOU Gengshen being independent non-executive directors of the Company.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (i) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and (ii) there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Company Announcements” page of the GEM website at <http://www.hkgem.com> for 7 days from the date of its posting. This announcement will also be posted on the Company’s website at <http://www.lifetechmed.com>.*